clinical trial · NCT06514521
Post Marketing Study on Pluvicto in Korea
Metastatic Castration-resistant Prostate CancerLutetium vipivotide tetraxetan
brief summary
Post marketing study on Pluvicto in Korea
started
Apr 18, 2025
primary completion
May 31, 2028
completion
May 31, 2028
last updated
Dec 30, 2025
detailed description
This is open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Pluvicto in patients with mCRPC in the real-world setting in South Korea.
official title
A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol